The latest price target for Virios Therapeutics (NASDAQ:VIRI) was reported by HC Wainwright & Co. on August 9, 2024. The analyst firm set a price target for $0.20 expecting VIRI to fall to within 12 months (a possible -6.85% downside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Virios Therapeutics (NASDAQ:VIRI) was provided by HC Wainwright & Co., and Virios Therapeutics maintained their neutral rating.

There is no last upgrade for Virios Therapeutics

The last downgrade for Virios Therapeutics Inc happened on September 20, 2022 when HC Wainwright & Co. changed their price target from N/A to N/A for Virios Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Virios Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Virios Therapeutics was filed on August 9, 2024 so you should expect the next rating to be made available sometime around August 9, 2025.

While ratings are subjective and will change, the latest Virios Therapeutics (VIRI) rating was a maintained with a price target of $0.40 to $0.20. The current price Virios Therapeutics (VIRI) is trading at is $0.21, which is out of the analyst’s predicted range.